The Effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis

Fa Mee Doh, Tae Ik Chang, Hyang Mo Koo, Mi Jung Lee, Dong Ho Shin, Chan Ho Kim, Kwang Il Ko, Hyung Jung Oh, TaeHyun Yoo, Shin-Wook Kang, Dae Suk Han, SeungHyeok Han

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background Insulin resistance is associated with the progression of atherosclerosis and is reported to predict cardiovascular mortality in patients with end-stage renal disease (ESRD). Although statins exert pleiotropic effects, it is uncertain whether statin therapy improves insulin resistance in these patients. In this prospective randomized controlled trial, we aimed to evaluate the effects of statin on insulin resistance among 70 patients undergoing peritoneal dialysis (PD). Methods Patients were randomized into a statin group (n0 35) or a control group (n035). The statin group received 10 mg per day of rosuvastatin for 6 months. We determined insulin resistance by homeostatic model assessment of insulin resistance (HOMA-IR) index. Serum concentrations of adipokines such as adiponectin, leptin, and resistin were measured using enzyme-linked immunosorbent (ELISA) assay. As inflammatory markers, high sensitive C-reactive protein (hsCRP) and interleukin-6 were also measured. Results There were no significant differences in baseline characteristics between the two groups. Compared to baseline value, statin treatment significantly decreased HOMA-IR index from 2.37±1.08 to 2.05±0.82 (P00.014). There was a concordant decrease in hsCRP levels in the statin group (2.05 ±1.57 to 1.21±0.84 mg/L, P0.001), but such improvements were not observed in the control group.When between-group differences in these parameters were compared, hsCRP levels were more decreased in the statin group than in the control group (P00.021 for between-group difference), whereas HOMA-IR index was not (P00.189 for between-group difference). During this period, statin treatment did not result in the improved adipokine profiles. Conclusion This study showed that statin therapy failed to improve insulin resistance in PD patients despite a significant decline in hsCRP levels after statin treatment. Our finding suggests that reducing inflammation by statin is of limited help to fully attenuate insulin resistance in these patients.

Original languageEnglish
Pages (from-to)501-509
Number of pages9
JournalCardiovascular Drugs and Therapy
Volume26
Issue number6
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Peritoneal Dialysis
Insulin Resistance
C-Reactive Protein
Adipokines
Control Groups
Enzyme-Linked Immunosorbent Assay
Resistin
Therapeutics
Adiponectin
Leptin
Chronic Kidney Failure
Interleukin-6
Atherosclerosis

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Doh, Fa Mee ; Chang, Tae Ik ; Koo, Hyang Mo ; Lee, Mi Jung ; Shin, Dong Ho ; Kim, Chan Ho ; Ko, Kwang Il ; Oh, Hyung Jung ; Yoo, TaeHyun ; Kang, Shin-Wook ; Han, Dae Suk ; Han, SeungHyeok. / The Effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis. In: Cardiovascular Drugs and Therapy. 2012 ; Vol. 26, No. 6. pp. 501-509.
@article{9baedf5152114f25b08991b4f792a4fd,
title = "The Effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis",
abstract = "Background Insulin resistance is associated with the progression of atherosclerosis and is reported to predict cardiovascular mortality in patients with end-stage renal disease (ESRD). Although statins exert pleiotropic effects, it is uncertain whether statin therapy improves insulin resistance in these patients. In this prospective randomized controlled trial, we aimed to evaluate the effects of statin on insulin resistance among 70 patients undergoing peritoneal dialysis (PD). Methods Patients were randomized into a statin group (n0 35) or a control group (n035). The statin group received 10 mg per day of rosuvastatin for 6 months. We determined insulin resistance by homeostatic model assessment of insulin resistance (HOMA-IR) index. Serum concentrations of adipokines such as adiponectin, leptin, and resistin were measured using enzyme-linked immunosorbent (ELISA) assay. As inflammatory markers, high sensitive C-reactive protein (hsCRP) and interleukin-6 were also measured. Results There were no significant differences in baseline characteristics between the two groups. Compared to baseline value, statin treatment significantly decreased HOMA-IR index from 2.37±1.08 to 2.05±0.82 (P00.014). There was a concordant decrease in hsCRP levels in the statin group (2.05 ±1.57 to 1.21±0.84 mg/L, P0.001), but such improvements were not observed in the control group.When between-group differences in these parameters were compared, hsCRP levels were more decreased in the statin group than in the control group (P00.021 for between-group difference), whereas HOMA-IR index was not (P00.189 for between-group difference). During this period, statin treatment did not result in the improved adipokine profiles. Conclusion This study showed that statin therapy failed to improve insulin resistance in PD patients despite a significant decline in hsCRP levels after statin treatment. Our finding suggests that reducing inflammation by statin is of limited help to fully attenuate insulin resistance in these patients.",
author = "Doh, {Fa Mee} and Chang, {Tae Ik} and Koo, {Hyang Mo} and Lee, {Mi Jung} and Shin, {Dong Ho} and Kim, {Chan Ho} and Ko, {Kwang Il} and Oh, {Hyung Jung} and TaeHyun Yoo and Shin-Wook Kang and Han, {Dae Suk} and SeungHyeok Han",
year = "2012",
month = "12",
day = "1",
doi = "10.1007/s10557-012-6412-2",
language = "English",
volume = "26",
pages = "501--509",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "6",

}

The Effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis. / Doh, Fa Mee; Chang, Tae Ik; Koo, Hyang Mo; Lee, Mi Jung; Shin, Dong Ho; Kim, Chan Ho; Ko, Kwang Il; Oh, Hyung Jung; Yoo, TaeHyun; Kang, Shin-Wook; Han, Dae Suk; Han, SeungHyeok.

In: Cardiovascular Drugs and Therapy, Vol. 26, No. 6, 01.12.2012, p. 501-509.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis

AU - Doh, Fa Mee

AU - Chang, Tae Ik

AU - Koo, Hyang Mo

AU - Lee, Mi Jung

AU - Shin, Dong Ho

AU - Kim, Chan Ho

AU - Ko, Kwang Il

AU - Oh, Hyung Jung

AU - Yoo, TaeHyun

AU - Kang, Shin-Wook

AU - Han, Dae Suk

AU - Han, SeungHyeok

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background Insulin resistance is associated with the progression of atherosclerosis and is reported to predict cardiovascular mortality in patients with end-stage renal disease (ESRD). Although statins exert pleiotropic effects, it is uncertain whether statin therapy improves insulin resistance in these patients. In this prospective randomized controlled trial, we aimed to evaluate the effects of statin on insulin resistance among 70 patients undergoing peritoneal dialysis (PD). Methods Patients were randomized into a statin group (n0 35) or a control group (n035). The statin group received 10 mg per day of rosuvastatin for 6 months. We determined insulin resistance by homeostatic model assessment of insulin resistance (HOMA-IR) index. Serum concentrations of adipokines such as adiponectin, leptin, and resistin were measured using enzyme-linked immunosorbent (ELISA) assay. As inflammatory markers, high sensitive C-reactive protein (hsCRP) and interleukin-6 were also measured. Results There were no significant differences in baseline characteristics between the two groups. Compared to baseline value, statin treatment significantly decreased HOMA-IR index from 2.37±1.08 to 2.05±0.82 (P00.014). There was a concordant decrease in hsCRP levels in the statin group (2.05 ±1.57 to 1.21±0.84 mg/L, P0.001), but such improvements were not observed in the control group.When between-group differences in these parameters were compared, hsCRP levels were more decreased in the statin group than in the control group (P00.021 for between-group difference), whereas HOMA-IR index was not (P00.189 for between-group difference). During this period, statin treatment did not result in the improved adipokine profiles. Conclusion This study showed that statin therapy failed to improve insulin resistance in PD patients despite a significant decline in hsCRP levels after statin treatment. Our finding suggests that reducing inflammation by statin is of limited help to fully attenuate insulin resistance in these patients.

AB - Background Insulin resistance is associated with the progression of atherosclerosis and is reported to predict cardiovascular mortality in patients with end-stage renal disease (ESRD). Although statins exert pleiotropic effects, it is uncertain whether statin therapy improves insulin resistance in these patients. In this prospective randomized controlled trial, we aimed to evaluate the effects of statin on insulin resistance among 70 patients undergoing peritoneal dialysis (PD). Methods Patients were randomized into a statin group (n0 35) or a control group (n035). The statin group received 10 mg per day of rosuvastatin for 6 months. We determined insulin resistance by homeostatic model assessment of insulin resistance (HOMA-IR) index. Serum concentrations of adipokines such as adiponectin, leptin, and resistin were measured using enzyme-linked immunosorbent (ELISA) assay. As inflammatory markers, high sensitive C-reactive protein (hsCRP) and interleukin-6 were also measured. Results There were no significant differences in baseline characteristics between the two groups. Compared to baseline value, statin treatment significantly decreased HOMA-IR index from 2.37±1.08 to 2.05±0.82 (P00.014). There was a concordant decrease in hsCRP levels in the statin group (2.05 ±1.57 to 1.21±0.84 mg/L, P0.001), but such improvements were not observed in the control group.When between-group differences in these parameters were compared, hsCRP levels were more decreased in the statin group than in the control group (P00.021 for between-group difference), whereas HOMA-IR index was not (P00.189 for between-group difference). During this period, statin treatment did not result in the improved adipokine profiles. Conclusion This study showed that statin therapy failed to improve insulin resistance in PD patients despite a significant decline in hsCRP levels after statin treatment. Our finding suggests that reducing inflammation by statin is of limited help to fully attenuate insulin resistance in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84876417114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876417114&partnerID=8YFLogxK

U2 - 10.1007/s10557-012-6412-2

DO - 10.1007/s10557-012-6412-2

M3 - Article

VL - 26

SP - 501

EP - 509

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 6

ER -